WeDaita  |  AI Drug Discovery Platform
BioMedAI From Target to Candidate — in One Platform

An end-to-end AI platform for drug discovery researchers. Identify novel targets, design protein & antibody therapeutics, and accelerate small molecule optimisation — all within a single intelligent workflow.

90%
Reduced Research Time
70%
Drug Design Cycle
2×
Clinical Trial Excution
  Try BioMedAI   See It in Action   Book a Call

Solving Drug Discovery at Scale

Drug discovery has long been defined by decade-long timelines, billion-dollar costs, and high failure rates. WeDaita is changing that — with AI agents built to compress timelines, cut costs, and improve decision quality at every stage of the pipeline.

90%
Failure Rate
9 in 10 drug candidates fail — most due to poor target validation and inadequate early-stage evidence. WeDaita's DBRA agents surface higher-confidence targets from the start.
10–15
Years per Drug
A decade-plus of research, design, and trials before patients see results. WeDaita compresses the early discovery pipeline from years to weeks.
$2–3B
Per Drug Candidate
Billions spent per approved drug — driven by inefficiency and late-stage failures. WeDaita reduces the cost burden by cutting wasted research cycles early.
BioMedAI Platform

One Platform. Full Discovery Pipeline.

Three agent modules that cover the complete drug discovery workflow — from target to candidate.

2 Agents Live
Stage 1 — Early Research
DBRA
Deep Biomedical Research Agents
Solves the Haystack Problem — automating evidence synthesis to generate and validate novel drug targets — in hours, not months.
  • Deep Research on drug research
  • Disease-to-target hypothesis generation
  • Drug Target PrioritizationIn Dev
  • Drug RepurposingIn Dev
90%
Reduction in early research time
1 Agent Live
Stage 2 — Drug Design
ADDA
Autonomous Drug Design Agents
Bridges the Translation Gap — automating biologic and small molecule drug design to reduce preclinical failure rates.
  • Protein / antibody drug design
  • Peptide/MacrocycleIn Dev
  • Small molecule design & optimisationIn Dev
70%
Faster drug design cycles (projected)
Roadmap
Stage 3 — Clinical Trials
CTIA
Clinical Trial Intelligence Agents
Addresses Late-Stage Attrition — AI-assisted protocol design, predictive recruitment, and portfolio optimization.
  • Digital twin trial simulationRoadmap
  • Predictive patient recruitmentRoadmap
  • AI-assisted protocol designRoadmap
  • Portfolio optimizationRoadmap
2×
Faster clinical trial execution (vision)

Experience AI-Powered Drug Discovery

Watch our autonomous AI Scientists platform accelerate research from months to minutes

  • Real-time demonstration of AI agents in action
  • Target identification in minutes, not months
  • Comprehensive insights from 11 biomedical databases
  • Autonomous research with zero human intervention

Grounded in Primary Scientific Sources

Every insight traces back to PubMed, UniProt, ChEMBL, PDB, and 7+ other primary databases — not black-box outputs.

Built by Drug Discovery Scientists

Our team has decades of combined experience in computational biology, medicinal chemistry, and AI research.

Researcher in the Loop, Always

BioMedAI accelerates your thinking — your scientific judgement drives every key decision.

What Will You Work On Today?

Choose Your Discovery Workflow

BioMedAI adapts to where you are in the pipeline. Start from any stage.

1
DBRA · Live Now Deep Research on drug research
I need to explore biomedical literature for a disease or target area
DBRA agents scan 11+ biomedical databases in parallel — PubMed, UniProt, OMIM, DisGeNET and more — delivering ranked, evidence-backed insights in hours, not months.
Try DBRA
2
DBRA · Live Now Disease-to-target hypothesis generation
I need to identify novel drug targets for a disease
DBRA maps disease pathways and proposes high-confidence target candidates with traceable, evidence-backed reasoning — ready for experimental validation.
Try DBRA
3
DBRA · In Development Drug Target Prioritization
I need to rank and score a shortlist of drug targets
Coming soon — DBRA's prioritisation module will score targets by druggability, novelty, and clinical evidence strength.
Get Notified
4
DBRA · In Development Drug Repurposing
I need to find repositioning opportunities for existing drugs
Coming soon — DBRA's repurposing agent cross-references approved compounds against emerging disease mechanisms to surface unexpected matches.
Get Notified
5
ADDA · Live Now Protein / antibody drug design
I need to design a protein or antibody therapeutic
ADDA agents generate, score, and optimise therapeutic candidates — including affinity maturation and developability assessment for your target.
Try ADDA
6
ADDA · In Development Peptide/Macrocycle
I need to design a peptide or macrocycle drug
In development — ADDA's peptide module will generate constrained peptide scaffolds with optimised binding and cell permeability profiles.
Get Notified
7
ADDA · In Development Small molecule design & optimisation
I need to optimise a small molecule hit series
In development — ADDA will generate ADMET-aware analogues and scaffold hops from your initial hit using generative chemistry with property guardrails.
Get Notified

The Team Behind BioMedAI

Scientists, engineers, and domain experts united by one mission — making drug discovery faster and smarter.

Wenliang Zhang
Wenliang Zhang
Daitor
All Members  
Stay Ahead

AI Drug Discovery, Delivered Monthly

Get curated insights on AI-driven target identification, therapeutic design, and BioMedAI platform updates — directly to your inbox.

No spam. Unsubscribe at any time. We respect your privacy.

Ready to Accelerate Your Drug Discovery?

BioMedAI is live — start with target identification and protein drug design today, with more modules launching soon.

  Try BioMedAI   Book a Demo